Replies to post #8933 on Arch Therapeutics Inc (ARTH)

[512]

Yes. Arth is finished. Lol. Other than the article did you reasearch what the product actually is?

Instead of posting about this product for info purposes you have to write is ARTH finished.

You're such a jackass

[Polyphemus]

ARTH may or may not succeed, but it is unlikely that AxioStat will be the cause for either result. The US Army used a similar product for several years before concluding that the device wasw no better than plain gauze and discontinued purchases. Also, AC5 and AxioStat do not have the same mechanism of action; these are two very different products. Finally, the statements that both Harvard and Stanford are in a research collaboration with the Indian firm implies considerably more than it actually says. AxioStat would be a low tech Class II device, hardly novel or worthy of a big name research collaboration.

[Polyphemus]

2nd comment on your post about ARTH...price of Axiostat in India is 2000 rupees, which translates into about $28.50 at current exchange rates; not $1.00 as alleged

Also, looking at 510(K) for Axiostat, predicate device in 510(K) is almost identical to Axiostat. Manufactured by US company, already targeting the same non-hospital market segment. Axiostat current sales are in India and Middle East. US subsidiary in Mass estabolished to allow markleting to US military (regulatory compliance issue).

To my knowledge, Axostat has patent coverage in India, but none in US, which makes sense as SAM Medical has virtually identical product on the market for several years.

Research "at Harvard" is actually studies with individual scientists, not university. Scientists are Indian researchers.

A little info goes a long way.....